TrialAssure launches Anonymize 3.0 for improved data, document anonymization in pharma and beyond

CANTON TWP.–TrialAssure, a pharmaceutical technology provider advancing clinical trial disclosure, data sharing, and transparency, announced that its flagship product TrialAssure Anonymize 3.0 is now available.

Anonymize allows users across the pharmaceutical industry the ability to perform data, document, and image anonymization and redaction using machine learning, natural language processing, and artificial intelligence to share information with confidence, knowing that patient and company confidential information are protected.

In this latest version, Anonymize 3.0 now includes the following:
* Enhanced user experience, with modernized design and intuitive navigation
* Centralized workbench structure for a comprehensive view of all projects and tasks in one location
* Updated rule structure for a streamlined and efficient and practical anonymization decision-making
* Extended support for additional types of documents, such as Microsoft Office documents and email
* Improved risk score visualization to track progress in mitigating re-identification risks

“This launch ushers in a new era in anonymization to the industry, one which combines advances in AI and deep industry knowledge to drive technological progress in the pharmaceutical industry,” said Zach Weingarden, TrialAssure director of product solutions. “With the technical and visual improvements to Anonymize, the most important information is now at the forefront and is easier to understand.”

TrialAssure Anonymize 3.0 gives users the ability to anonymize more documents, including pre-existing PDF functionality and new document types, including emails and Microsoft Office documents (Word, Excel, and PowerPoint). For data, Anonymize 3.0 supports SAS, XPT, Excel, and CSV file formats.

The need for anonymization extends beyond the pharmaceutical industry into government, finance, legal, and numerous others. With this, TrialAssure is incorporating these significant Anonymize 3.0 updates into its Trusano.AI platform, where non-pharma users can use anonymization, redaction, and masking technology for protecting commercially confidential information and personal protected data.

“Data is today’s currency, and it needs to be protected in the proper fashion,” said TrialAssure Senior Manager of Business Development James Green. “Fulfilling requests under the Freedom of Information Act is an ideal use case for Trusano.AI, as the technology can move to reduce backlog and enhance transparency in a fast, affordable manner.”

For more information or to request a demonstration, visit or

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.